Results 231 to 240 of about 46,843 (269)
Some of the next articles are maybe not open access.
Journal of dermatological treatment (Print), 2019
Background: There has been an alarming increase in recalcitrant dermatophytosis in recent years. The standard treatment guidelines no longer seem effective in achieving clearance and results in high failure rates.
Priyanka Sharma+3 more
semanticscholar +1 more source
Background: There has been an alarming increase in recalcitrant dermatophytosis in recent years. The standard treatment guidelines no longer seem effective in achieving clearance and results in high failure rates.
Priyanka Sharma+3 more
semanticscholar +1 more source
Itraconazole for the treatment of onychomycosis
International Journal of Dermatology, 1998Background The broad spectrum of activity of itraconazole in vitro manifests itself clinically with the drug being effective for the treatment of onychomycosis caused by dermatophytes, Candida and some non‐dermatophyte molds. The pharmacokinetics of itraconazole in the nail results in drug remaining at therapeutic levels for 6–9 months after ...
Ralph Daniel+6 more
openaire +3 more sources
Itraconazole in Cyclodextrin Solution [PDF]
Itraconazole, a water‐insoluble oral triazole antifungal, has been formulated in cyclodextrin as a solution. Cyclodextrin is a ring of glucose molecules that can accept a lipophilic guest molecule within the ring. This enables solubilization and delivery to the lipid interface of the gut lumen, resulting in absorption of the guest molecule without ...
openaire +2 more sources
Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND SUper BioAvailability-itraconazole (SUBA®-itraconazole) was introduced into Australia in April 2014 as a substitute for standard itraconazole on the basis of improved bioavailability, tolerance and interpatient variability.
B. Nield, S. Larsen, S. V. van Hal
semanticscholar +1 more source
BACKGROUND SUper BioAvailability-itraconazole (SUBA®-itraconazole) was introduced into Australia in April 2014 as a substitute for standard itraconazole on the basis of improved bioavailability, tolerance and interpatient variability.
B. Nield, S. Larsen, S. V. van Hal
semanticscholar +1 more source
Treatment of Mycoses with Itraconazole
Annals of the New York Academy of Sciences, 1988The efficacy of itraconazole, a new oral triazole, was evaluated at doses of 50-400 mg/day in 64 courses: 39 with coccidioidomycosis, and 25 with other mycoses. Among patients with coccidioidomycosis, 21 had pulmonary disease; 10, bone and joint; 8, lymphatic; 6, skin and soft tissue; 3, meningeal; and 1, urogenital.
Paul L. Williams+3 more
openaire +3 more sources
Itraconazole interacts with felodipine
Journal of the American Academy of Dermatology, 199515. Hung W, August GP. A "collagen like" syndrome associated with antithyroid therapy. J Pediatr 1973;82:852-4. 16. Amrhein JA, Kenny FM, Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr 1970;76:54-63. 17. Griswold WR, Mendoza SA, Johnston W.
Raimo Suhonen, Pertti J. Neuvonen
openaire +3 more sources
Treatment of Chromoblastomycosis with Itraconazole
Annals of the New York Academy of Sciences, 1988The results of long-term itraconazole therapy in 10 patients with active chromoblastomycosis due to F. pedrosoi were reported. Therapy consisted of 100 or 200 mg/day of itraconazole, the length of therapy depending on the patient's response (12 to 24 months).
Aurelio Gonzalez+4 more
openaire +3 more sources
Itraconazole in the Treatment of Coccidioidomycosis
Chest, 1991Sixteen patients with coccidioidomycosis were treated with itraconazole for one year. Sixteen suffered from pulmonary coccidioidomycosis, two of them had associated mediastinal lesions, and one suffered from skin coccidioidomycosis. The daily dose used was 400 mg during the one-year period.
S Cruz, M Diaz, L A de Hoyos, R Puente
openaire +3 more sources
Itraconazole in Antifungal Therapy
Annals of Pharmacotherapy, 1992OBJECTIVE: This overview compares and contrasts the pharmacotherapy of itraconazole with that of other antifungal agents. DATA SOURCES: Primary literature on itraconazole was identified through a medical literature search from 1976 through 1991. This search included journal articles, abstracts, conference proceedings, and reports of animal and human ...
Jerry W. Taylor+2 more
openaire +3 more sources
Itraconazole treatment of phaeohyphomycosis
Journal of the American Academy of Dermatology, 1990Nineteen patients with phaeohyphomycosis were treated with itraconazole. Of these, 17 were assessable for clinical outcome. Of these, two had received no prior therapy, five had failed amphotericin B therapy, four had failed ketoconazole or miconazole therapy, and five had failed both amphotericin B and azole therapy.
Paul D. Hoeprich+16 more
openaire +3 more sources